PEDIATRICS Vol. 55 No. 3 March 1975, pp. 308-310
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bleyer, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bleyer, W. A.

Surveillance of pediatric adverse drug reactions: A neglected health care program

W. Archie Bleyer M.D.1

1 Children's Orthopedic Hospital and Medical Center, 4800 Sand Point Way, N.E. Seattle, Washington 98105

Dr. Alan K. Done, Director of Pediatric Pharmacology for the Food and Drug Administration, has recently secured a commitment from the pharmaceutical industry to complete preclinical studies of the many drugs which have not as yet been tested in young animals and are therefore not currently available for use in children. Once accomplished, this action and others already taken by the agency should help solve the problem of "therapeutic orphans."1 On the other hand, young children continue to be exposed to a large number of drugs which are already on the market and which are being given without adequate medical supervision or monitoring for adverse reactions.